Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer’s Disease
暂无分享,去创建一个
Denis Getsios | D. Getsios | Steve Blume | K. Jack Ishak | Grant D. H. Maclaine | S. Blume | G. Maclaine | K. Ishak
[1] Jaime J Caro,et al. NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used? , 2007, PharmacoEconomics.
[2] J. Brazier,et al. The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.
[3] R. Hansen,et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis , 2008, Clinical interventions in aging.
[4] M. Oremus. Systematic review of economic evaluations of Alzheimer’s disease medications , 2008, Expert review of pharmacoeconomics & outcomes research.
[5] J. Caro,et al. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK , 2003, PharmacoEconomics.
[6] Alexander von Eye,et al. Predictive validity of neuropsychiatric subgroups on nursing home placement and survival in patients with Alzheimer disease. , 2007, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[7] B. Winblad,et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD , 2001, Neurology.
[8] R. Mohs,et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.
[9] J. Ashford,et al. Modelling mini mental state examination changes in Alzheimer's disease. , 2000, Statistics in medicine.
[10] Gunhild Waldemar,et al. Patient- and Proxy-Reported Utility in Alzheimer Disease Using the EuroQoL , 2006, Alzheimer disease and associated disorders.
[11] L. Williams,et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease , 1999, Neurology.
[12] J. Caro,et al. Assessment of health economics in Alzheimer’s disease (AHEAD) based on need for full-time care , 2001, Neurology.
[13] H. Feldman,et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease , 2001, Neurology.
[14] C. Green,et al. Modelling Disease Progression in Alzheimer’s Disease , 2012, PharmacoEconomics.
[15] R. Mohs,et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.
[16] Dirk Deleu,et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. , 2001, Neurology.
[17] G. Jackson,et al. Role of cholinesterase inhibitors in dementia care needs rethinking , 2006, BMJ : British Medical Journal.
[18] R. Mohs,et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.
[19] Joshua T. Cohen,et al. Decision analytic models for Alzheimer's disease: State of the art and future directions , 2008, Alzheimer's & Dementia.
[20] Sture Eriksson,et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study , 2006, The Lancet.
[21] R. Mohs,et al. Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease. , 2000, Statistics in medicine.
[22] B. Winblad,et al. 3-Year Study of Donepezil Therapy in Alzheimer’s Disease: Effects of Early and Continuous Therapy , 2006, Dementia and Geriatric Cognitive Disorders.
[23] K. Davis. Cholinesterase Inhibitors in Alzheimer's Disease , 1994, Neuropsychopharmacology.
[24] B. Gordon,et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. , 2001, Archives of neurology.
[25] S. E. Black,et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease , 2007, Neurology.
[26] D. Jolley,et al. Treatment of a Whole Population Sample of Alzheimer’s Disease with Donepezil over a 4-Year Period: Lessons Learned , 2008, Dementia and Geriatric Cognitive Disorders.
[27] Jing Xie,et al. Survival times in people with dementia: analysis from population based cohort study with 14 year follow-up , 2008, BMJ : British Medical Journal.
[28] K. Davis,et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. , 1994, The American journal of psychiatry.
[29] C. Green. Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis. , 2007, PharmacoEconomics.
[30] Boris OGUIBENINE,et al. Long-term care and dementia services: an impending crisis. , 2006, Age and ageing.